Aim: The aim of our study was to investigate whether treatment with red yeast rice added with Coenzyme Q10 is associated with changes in endothelial function and arterial stiffness. Methods: This double blind, placebo-controlled, randomized clinical trial was carried out on 40 non-smoker moderately hypercholesterolemic subjects (ClinicalTrial.gov ID NCT02492464). After 4 weeks of diet and physical activity, patients were allocated to treatment with placebo or with an active product containing 10 mg monacolins and 30 mg Coenzyme Q10, to be assumed for 6 months. Endothelial reactivity and arterial stiffness have been measured through the validated Vicorder® device. Results: During monacolin treatment, patients experienced a more favorable percentage change in low density lipoprotein (LDL)-cholesterol (after monacolin treatment: -26.3%; after placebo treatment: +3.4%, p < 0.05). Endothelial reactivity (pulse volume displacement after monacolin treatment: +6.0%; after placebo treatment: -0.3%, p < 0.05), and arterial stiffness (pulse wave velocity (PWV) after monacolin treatment: -4.7%; after placebo: +1.1%, p < 0.05) also significantly improved only after monacolin treatment. Conclusion: The long-term assumption of the tested dietary supplement is associated with an improvement in LDL-cholesterolemia, endothelial reactivity and PWV in moderately hypercholesterolemic subjects.

Keywords:
Monacolins, Low-density lipoprotein-cholesterol, Coenzyme Q10, Nutraceuticals, Clinical trial
1.
Cicero AF, Colletti A: Combinations of phytomedicines with different lipid lowering activity for dyslipidemia management: the available clinical data. Phytomedicine 2015;pii:S0944-7113(15)00330-X.
2.
Cicero AF, Ferroni A, Ertek S: Tolerability and safety of commonly used dietary supplements and nutraceuticals with lipid-lowering effects. Expert Opin Drug Saf 2012;11:753-766.
3.
Derosa G, Maffioli P, Cicero AF: Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials. Expert Opin Biol Ther 2012;12:1113-1124.
4.
Derosa G, Cicero AF, Fogari E, D'Angelo A, Bonaventura A, Maffioli P: Effects of n-3 PUFA on insulin resistance after an oral fat load. Eur J Lipid Sci Technol 2011;113:950-960.
5.
Derosa G, Cicero AF, Fogari E, D'Angelo A, Bonaventura A, Romano D, Maffioli P: Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp and oral fat load. J Clin Lipidol 2012;6:553-564.
6.
Heber D, Lembertas A, Lu QY, Bowerman S, Go VL: An analysis of nine proprietary Chinese red yeast rice dietary supplements: implications of variability in chemical profile and contents. J Altern Complement Med 2001;7:133-139.
7.
Ma J, Li Y, Ye Q, Li J, Hua Y, Ju D, Zhang D, Cooper R, Chang M: Constituents of red yeast rice, a traditional Chinese food and medicine. J Agric Food Chem 2000;48:5220-5225.
8.
Goldstein MR: Effects of dietary phytosterols on cholesterol metabolism and atherosclerosis. Am J Med 2000;109:72-73.
9.
Zhu L, Yau LF, Lu JG, Zhu GY, Wang JR, Han QB, Hsiao WL, Jiang ZH: Cytotoxic dehydromonacolins from red yeast rice. J Agric Food Chem 2012;60:934-939.
10.
Zhu L, Lu JG, Li T, Zhu GY, Han QB, Hsiao WL, Liu L, Jiang ZH: Immunosuppressive decalin derivatives from red yeast rice. J Nat Prod 2012;75:567-571.
11.
Hasani-Ranjbar S, Nayebi N, Moradi L, Mehri A, Larijani B, Abdollahi M: The efficacy and safety of herbal medicines used in the treatment of hyperlipidemia; a systematic review. Curr Pharm Des 2010;16:2935-2947.
12.
Wang J, Su M, Lu Z, et al: Clinical trial of extract of Monascus purpureus (red yeast) in the treatment of hyperlipidemia. Chin J Exp Ther Prep Chin Med 1995;12:1-5.
13.
Lin CC, Li TC, Lai MM: Efficacy and safety of monascus purpureus went rice in subjects with hyperlipidemia. Eur J Endocrinol 2005;153:679-686.
14.
Heber D, Yip I, Ashley JM, Elashoff DA, Elashoff RM, Go VL: Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr 1999;69:231-236.
15.
Bogsrud MP, Ose L, Langslet G, Ottestad I, Strøm EC, Hagve TA, Retterstøl K: HypoCol (red yeast rice) lowers plasma cholesterol - a randomized placebo controlled study. Scand Cardiovasc J 2010;44:197-200.
16.
Guardamagna O, Abello F, Baracco V, Stasiowska B, Martino F: The treatment of hypercholesterolemic children: efficacy and safety of a combination of red yeast rice extract and policosanols. Nutr Metab Cardiovasc Dis 2011;21:424-429.
17.
Cicero AF, Derosa G, Borghi C: Red yeast rice and statin-intolerant patients. Am J Cardiol 2010;105:1504.
18.
Halbert SC, French B, Gordon RY, Farrar JT, Schmitz K, Morris PB, Thompson PD, Rader DJ, Becker DJ: Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am J Cardiol 2010;105:198-204.
19.
European Food Safety Authority: Scientific opinion on the substantiation of health claims related to monacolin K from red yeast rice and maintenance of normal blood LDL-cholesterol concentrations (ID 1648, 1700) pursuant to article 13(1) of regulation (EC) No 1924/2006. EFSA J 2011;9:2304.
20.
Cicero AF, Derosa G, Parini A, Maffioli P, D'Addato S, Reggi A, Giovannini M, Borghi C: Red yeast rice improves lipid pattern, high-sensitivity C-reactive protein, and vascular remodeling parameters in moderately hypercholesterolemic Italian subjects. Nutr Res 2013;33:622-628.
21.
Borner K, Klose S: [Enzymatic determination of total cholesterol with the greiner selective analyzer (GSA-II) (author's transl)]. J Clin Chem Clin Biochem 1977;15:121-130.
22.
Havel RJ, Eder HA, Bragdon JH: The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955;34:1345-1353.
23.
Wahlefeld AW: Triglycerides determination after enzymatic hydrolysis; in Bermeyer Hu (ed): Methods of Enzymatic Analysis, ed 2. New York, Academic Press, 1974, pp 18-31.
24.
Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
25.
Cicero AF, D'Addato S, Reggi A, Reggiani GM, Borghi C: Hepatic steatosis index and lipid accumulation product as middle-term predictors of incident metabolic syndrome in a large population sample: data from the Brisighella heart study. Intern Emerg Med 2013;8:265-267.
26.
Day LM, Maki-Petaja KM, Wilkinson IB, McEniery CM: Assessment of brachial artery reactivity using the Endocheck: repeatability, reproducibility and preliminary comparison with ultrasound. Artery Res 2013;7:119-120.
27.
Hickson SS, Butlin M, Broad J, Avolio AP, Wilkinson IB, McEniery CM: Validity and repeatability of the Vicorder apparatus: a comparison with the SphygmoCor device. Hypertens Res 2009;32:1079-1085.
28.
Pucci G, Cheriyan J, Hubsch A, Hickson SS, Gajendragadkar PR, Watson T, O'Sullivan M, Woodcock-Smith J, Schillaci G, Wilkinson IB, McEniery CM: Evaluation of the Vicorder, a novel cuff-based device for the noninvasive estimation of central blood pressure. J Hypertens 2013;31:77-85.
29.
Gerards MC, Terlou RJ, Yu H, Koks CH, Gerdes VE: Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain - a systematic review and meta-analysis. Atherosclerosis 2015;240:415-423.
30.
Affuso F, Mercurio V, Ruvolo A, Pirozzi C, Micillo F, Carlomagno G, Grieco F, Fazio S: A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome. World J Cardiol 2012;4:77-83.
31.
Affuso F, Ruvolo A, Micillo F, Saccà L, Fazio S: Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study. Nutr Metab Cardiovasc Dis 2010;20:656-661.
32.
Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R: Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the international brachial artery reactivity task force. J Am Coll Cardiol 2002;39:257-265.
33.
Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE: Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111-1115.
34.
Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-126.
35.
Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Menzoian JO, Vita JA: Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation 2002;105:1567-1572.
36.
Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA, Nour KR, Quyyumi AA: Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002;106:653-658.
37.
van Sloten TT, Henry RM, Dekker JM, Nijpels G, Unger T, Schram MT, Stehouwer CD: Endothelial dysfunction plays a key role in increasing cardiovascular risk in type 2 diabetes: the Hoorn study. Hypertension 2014;64:1299-1305.
38.
Calicchio R, Buffat C, Vaiman D, Miralles F: [Endothelial dysfunction: role in the maternal syndrome of preeclampsia and long-term consequences for the cardiovascular system]. Ann Cardiol Angeiol (Paris) 2013;62:215-220.
39.
Hirata Y, Sugiyama S, Yamamoto E, Matsuzawa Y, Akiyama E, Kusaka H, Fujisue K, Kurokawa H, Matsubara J, Sugamura K, Maeda H, Iwashita S, Jinnouchi H, Matsui K, Ogawa H: Endothelial function and cardiovascular events in chronic kidney disease. Int J Cardiol 2014;173:481-486.
40.
Principi M, Mastrolonardo M, Scicchitano P, Gesualdo M, Sassara M, Guida P, Bucci A, Zito A, Caputo P, Albano F, Ierardi E, Di Leo A, Ciccone MM: Endothelial function and cardiovascular risk in active inflammatory bowel diseases. J Crohns Colitis 2013;7:e427-e433.
41.
Van Bortel LM, Laurent S, Boutouyrie P, Chowienczyk P, Cruickshank JK, De Backer T, Filipovsky J, Huybrechts S, Mattace-Raso FU, Protogerou AD, Schillaci G, Segers P, Vermeersch S, Weber T; Artery Society; European Society of Hypertension Working Group on Vascular Structure and Function; European Network for Noninvasive Investigation of Large Arteries: Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens 2012;30:445-448.
42.
Van Sloten TT, Schram MT, van den Hurk K, Dekker JM, Nijpels G, Henry RM, Stehouwer CD: Local stiffness of the carotid and femoral artery is associated with incident cardiovascular events and all-cause mortality: the Hoorn study. J Am Coll Cardiol 2014;63:1739-1747.
43.
Larijani VN, Ahmadi N, Zeb I, Khan F, Flores F, Budoff M: Beneficial effects of aged garlic extract and coenzyme Q10 on vascular elasticity and endothelial function: the FAITH randomized clinical trial. Nutrition 2013;29:71-75.
44.
Young JM, Molyneux SL, Reinheimer AM, Florkowski CM, Frampton CM, Scott RS, George PM: Relationship between plasma coenzyme Q10, asymmetric dimethylarginine and arterial stiffness in patients with phenotypic or genotypic familial hypercholesterolemia on long-term statin therapy. Atherosclerosis 2011;218:188-193.
45.
Lee YJ, Cho WJ, Kim JK, Lee DC: Effects of coenzyme Q10 on arterial stiffness, metabolic parameters, and fatigue in obese subjects: a double-blind randomized controlled study. J Med Food 2011;14:386-390.
46.
Murrow JR, Sher S, Ali S, Uphoff I, Patel R, Porkert M, Le NA, Jones D, Quyyumi AA: The differential effect of statins on oxidative stress and endothelial function: atorvastatin versus pravastatin. J Clin Lipidol 2012;6:42-49.
47.
Kanaki AI, Sarafidis PA, Georgianos PI, Kanavos K, Tziolas IM, Zebekakis PE, Lasaridis AN: Effects of low-dose atorvastatin on arterial stiffness and central aortic pressure augmentation in patients with hypertension and hypercholesterolemia. Am J Hypertens 2013;26:608-616.
48.
Gao L, Mao Q, Cao J, Wang Y, Zhou X, Fan L: Effects of coenzyme Q10 on vascular endothelial function in humans: a meta-analysis of randomized controlled trials. Atherosclerosis 2012;221:311-316.
49.
Tomiyama H, Yamashina A: Non-invasive vascular function tests: their pathophysiological background and clinical application. Circ J 2010;74:24-33.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.